Autopsy report · NCT01425190

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

“The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free regimens in pediatric studies of HCV infection.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Hepatitis C, Chronic

Interventions

Boceprevir

Participants

16

Trials that died the same way

• Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
  “Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.